世界卫生组织《应对结核病及其共病合作行动框架》解读

doi:10.19982/j.issn.1000-6621.20220464

中国防痨杂志 ›› 2023, Vol. 45 ›› Issue (1): 25-30.doi: 10.19982/j.issn.1000-6621.20220464

世界卫生组织《应对结核病及其共病合作行动框架》解读

韩婷婷¹, 刘桂珍², 陈秋奇¹, 邓国防³()

¹广东医科大学第一临床医学院,湛江 524023
²赣南医学院第一临床医学院,赣州 341000
³广东医科大学附属深圳市第三人民医院肺病二科,深圳 518112

收稿日期:2022-11-23 出版日期:2023-01-10 发布日期:2022-12-30
通信作者: 邓国防 E-mail:jxxk1035@yeah.net
基金资助:
佛山市高水平医院登峰计划项目(FSSYKF-2020001);深圳市第三人民医院院内项目(G2021015);深圳市第三人民医院院内项目(G2022005)

Interpretation of Framework for collaborative action on tuberculosis and comorbidities

Han Tingting¹, Liu Guizhen², Chen Qiuqi¹, Deng Guofang³()

¹The First Clinical Medical College, Guangdong Medical University, Zhanjiang 524023, China
²The First Clinical Medical College, Gannan Medical University, Jiangxi Province, Ganzhou 341000, China
³The Second Department of Pulmonary Diseases, Shenzhen Third People’s Hospital Affiliated to the Guangdong Medical University, Shenzhen 518112, China

Received:2022-11-23 Online:2023-01-10 Published:2022-12-30
Contact: Deng Guofang E-mail:jxxk1035@yeah.net
Supported by:
Foshan High Level Hospital Peak Climbing Program Project(FSSYKF-2020001);Shenzhen Third People’s Hospital Foundation(G2021015);Shenzhen Third People’s Hospital Foundation(G2022005)

摘要/Abstract

摘要：

在全球范围内,结核病仍然是由单一传染性病原体导致死亡的主要原因之一。主要的结核病共病和与结核病相关的健康危险因素包括人类免疫缺陷病毒感染、酗酒、营养不良、吸烟、糖尿病、精神失常、矽肺和病毒性肝炎。应对结核病患者共病和相关健康危险因素对于终止结核病流行至关重要。为实现这一目标,诊疗、护理和关怀的重点应该放在患者上,而不是具体的疾病上,全球应致力于合作应对结核病及其共病问题。为此,2022年10月,世界卫生组织制定了《应对结核病及其共病合作行动框架》,框架分为5个部分,每部分均列出了有助于推广合作防控结核病及其共病问题的主要行动。笔者就该文件制定的行动框架概要、主要共病和行动原则等进行解读,以供相关专业工作者参考。

关键词: 世界卫生组织, 结核, 共病现象, 合作行为

Abstract:

Globally, tuberculosis (TB) remains one of the leading causes of death due to a single infectious agent. The main comorbidities and health-related risk factors of TB include human immunodeficiency virus (HIV), disorders due to the use of alcohol, undernutrition, tobacco smoking, diabetes mellitus, mental disorders, silicosis and viral hepatitis. Tacking both health-related risk factors and comorbidities among people with TB is essential for ending the TB epidemic. To achieve this, a well-rounded patient care approach is preferable to just targeting the disease alone. Substantial effort and global commitment are needed to achieve this collaboratively. Therefore, World Health Organization (WHO) has launched a framework for collaborative action on tuberculosis and comorbidities. The framework is organized into five sections, each of which lists key activities for scaling up joint efforts on TB and comorbidities. To know the contents of this document timely, we interpret the key points of the framework, key comorbidities and action principles to provide a reference for professionals.

Key words: World Health Organization, Tuberculosis, Comorbidity, Cooperative behavior

中图分类号:

韩婷婷, 刘桂珍, 陈秋奇, 邓国防. 世界卫生组织《应对结核病及其共病合作行动框架》解读[J]. 中国防痨杂志, 2023, 45(1): 25-30. doi: 10.19982/j.issn.1000-6621.20220464

Han Tingting, Liu Guizhen, Chen Qiuqi, Deng Guofang. Interpretation of Framework for collaborative action on tuberculosis and comorbidities[J]. Chinese Journal of Antituberculosis, 2023, 45(1): 25-30. doi: 10.19982/j.issn.1000-6621.20220464

参考文献 24

[1]	World Health Organization.Global tuberculosis report 2022. Geneva: World Health Organization, 2022.
[2]	World Health Organization. The end TB strategy. Geneva: World Health Organization, 2014.
[3]	World Health Organization. Framework for collaborative action on tuberculosis and comorbidities. Geneva: World Health Organization, 2022.
[4]	World Health Organization. Global tuberculosis report 2021. Geneva: World Health Organization, 2021.
[5]	World Health Organization. Global status report on alcohol and health 2018. Geneva: World Health Organization, 2018.
[6]	Ragan EJ, Kleinman MB, Sweigart B, et al. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. Int J Tuberc Lung Dis, 2020, 24(1): 73-82. doi:10.5588/ijtld.19.0080. doi: 10.5588/ijtld.19.0080 pmid: 32005309
[7]	Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med, 2008, 5(7): e152. doi:10.1371/journal.pmed.0050152. doi: 10.1371/journal.pmed.0050152.
[8]	Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med, 2011, 9: 81. doi:10.1186/1741-7015-9-81. doi: 10.1186/1741-7015-9-81 pmid: 21722362
[9]	Liu Q, Li W, Xue M, et al. Diabetes mellitus and the risk of multidrug resistant tuberculosis: a meta-analysis. Sci Rep, 2017, 7(1): 1090. doi:10.1038/s41598-017-01213-5. doi: 10.1038/s41598-017-01213-5 pmid: 28439071
[10]	Noubiap JJ, Nansseu JR, Nyaga UF, et al. Global prevalence of diabetes in active tuberculosis: a systematic review and meta-analysis of data from 2.3 million patients with tuberculosis. Lancet Glob Health, 2019, 7(4): e448-e460. doi:10.1016/S2214-109X(18)30487-X. doi: 10.1016/S2214-109X(18)30487-X.
[11]	World Health Organization. Tuberculosis: Fact Sheet. Geneva: World Health Organization, 2021.
[12]	World Health Organization. WHO TB burden estimates. Geneva: World Health Organization, 2021.
[13]	Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc, 2016, 19(1): 20714. doi:10.7448/IAS.19.1.20714. doi: 10.7448/IAS.19.1.20714 pmid: 26765347
[14]	Gupta RK, Lucas SB, Fielding KL, et al. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS, 2015, 29(15): 1987-2002. doi:10.1097/QAD.0000000000000802. doi: 10.1097/QAD.0000000000000802 pmid: 26266773
[15]	World Health Organization. WHO global report on trends in prevalence of tobacco use 2000—2025. Geneva: World Health Organization, 2021.
[16]	Ehrlich R, Akugizibwe P, Siegfried N, et al. The association between silica exposure, silicosis and tuberculosis: a systematic review and meta-analysis. BMC Public Health, 2021, 21(1): 953. doi:10.1186/s12889-021-10711-1. doi: 10.1186/s12889-021-10711-1 pmid: 34016067
[17]	Byrne AL, Marais BJ, Mitnick CD, et al. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis, 2015, 32: 138-146. doi:10.1016/j.ijid.2014.12.016. doi: 10.1016/j.ijid.2014.12.016 pmid: 25809770
[18]	Ho JC, Leung CC. Management of co-existent tuberculosis and lung cancer. Lung Cancer, 2018, 122: 83-87. doi:10.1016/j.lungcan.2018.05.030. doi: 10.1016/j.lungcan.2018.05.030. URL
[19]	Pedrazzoli D, Wingfield T. Biosocial Strategies to Address the Socioeconomic Determinants and Consequences of the TB and COVID-19 Pandemics. Am J Trop Med Hyg, 2021, 104(2): 407-409. doi:10.4269/ajtmh.20-1641. doi: 10.4269/ajtmh.20-1641. URL
[20]	Duko B, Bedaso A, Ayano G. The prevalence of depression among patients with tuberculosis: a systematic review and meta-analysis. Ann Gen Psychiatry, 2020, 19: 30. doi:10.1186/s12991-020-00281-8. doi: 10.1186/s12991-020-00281-8. URL
[21]	World Health Organization. Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016—2021: actions for impact. Geneva: World Health Organization, 2021.
[22]	Feleke BE, Feleke TE, Adane WG, et al. Impacts of hepatitis B and hepatitis C co-infection with tuberculosis, a prospective cohort study. Virol J, 2020, 17(1): 113. doi:10.1186/s12985-020-01385-z. doi: 10.1186/s12985-020-01385-z pmid: 32703225
[23]	Getahun H, Gunneberg C, Sculier D, et al. Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV AIDS, 2012, 7(4): 345-353. doi:10.1097/COH.0b013e328354bd44. doi: 10.1097/COH.0b013e328354bd44. URL
[24]	Bushnell G, Stennis NL, Drobnik AM, et al. Characteristics and TB treatment outcomes in TB patients with viral hepatitis, New York City, 2000—2010. Epidemiol Infect, 2015, 143(9): 1972-1981. doi:10.1017/S0950268814002970. doi: 10.1017/S0950268814002970.

世界卫生组织《应对结核病及其共病合作行动框架》解读

Interpretation of Framework for collaborative action on tuberculosis and comorbidities

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

友情链接

[1]	王前, 王嘉, 李玉红, 刘二勇, 周林. 重视儿童结核病防治关爱儿童健康[J]. 中国防痨杂志, 2023, 45(1): 1-5.
[2]	何小谋, 罗卉, 马进宝, 任斐, 赵阿利, 袁荣. “三位一体”的关怀服务对耐多药/利福平耐药结核病患者强化期治疗的影响[J]. 中国防痨杂志, 2023, 45(1): 104-110.
[3]	陶荔莹, 徐征, 赵鑫, 李艳圆, 李亚敏, 许琰, 张亚楠, 高志东. 2021年北京市高中及以下学段入学新生肺结核筛查结果分析[J]. 中国防痨杂志, 2023, 45(1): 111-115.
[4]	尚园园, 聂文娟, 黄海荣, 初乃惠. 抗结核药物贝达喹啉与氯法齐明耐药的研究现状[J]. 中国防痨杂志, 2023, 45(1): 116-122.
[5]	王泽明, 申阿东. 《儿童结核分枝杆菌潜伏感染检测和预防性治疗》标准解读[J]. 中国防痨杂志, 2023, 45(1): 13-17.
[6]	王泽明, 申阿东. 《儿童中枢神经系统结核的诊断》团体标准解读[J]. 中国防痨杂志, 2023, 45(1): 18-24.
[7]	李桂莲, 方敏, 姜靖伟, 王瑞欢, 钱程宇, 于晋杰, 曹滨, 许达, 赵秀芹, 李马超, 刘海灿, 孙琳, 朱渝, 万康林. 肺结核患儿胃液样本结核分枝杆菌培养阳性率提高方法的探讨[J]. 中国防痨杂志, 2023, 45(1): 31-37.
[8]	李翔, 付旭文, 许艳玲, 干玮, 杞敏, 黄瑛. CT征象联合外周血嗜酸性粒细胞对鉴别儿童胸肺型并殖吸虫病与结核性胸膜炎的价值研究[J]. 中国防痨杂志, 2023, 45(1): 38-44.
[9]	陈芳, 张小佛, 周海依, 张锋, 王曼知. 儿童抗结核药物性肝损伤状况及相关影响因素分析[J]. 中国防痨杂志, 2023, 45(1): 45-51.
[10]	任斐, 马进宝, 李荣, 杨翰, 杨虹, 武延琴, 杨新军, 党丽云. 高剂量莫西沙星短程方案对利福平耐药肺结核的疗效及适用性研究[J]. 中国防痨杂志, 2023, 45(1): 52-59.
[11]	樊丽超, 焦伟伟, 吴浩宇, 申阿东, 陈禹. 世界卫生组织《结核病整合指南模块5:儿童和青少年结核病管理》解读[J]. 中国防痨杂志, 2023, 45(1): 6-12.
[12]	余美玲, 张晨晨, 魏文静, 赵雨川, 卓文基, 郑磊. 体外诱导对氨基水杨酸高浓度耐药结核分枝杆菌及其突变位点研究[J]. 中国防痨杂志, 2023, 45(1): 60-66.
[13]	盛云峰, 邱美华, 陈园园, 孙丽芳, 甄利波. 树突细胞miR-17调节初始CD4⁺T淋巴细胞分化Treg/Th17失衡机制的研究[J]. 中国防痨杂志, 2023, 45(1): 67-72.
[14]	魏淑贞, 赵永, 林建, 林淑芳, 戴志松. 2017—2019年福建省结核分枝杆菌分离株基因型特征及其耐药性分析[J]. 中国防痨杂志, 2023, 45(1): 73-78.
[15]	徐银娟, 赵国连, 崔晓利, 党丽云, 康磊, 周永. 实时荧光RNA恒温检测在气管支气管结核疗效监测中的应用价值[J]. 中国防痨杂志, 2023, 45(1): 79-84.